GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

The recommendation by the Committee for Medicinal Products for Human Use--also known as CHMP--follows the approval of Blenrep combinations by the U.K.'s Medicines and Healthcare products Regulatory ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

(Alliance News) - GSK PLC on Friday said its drug Blenrep has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use.

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The FTSE 100 index closed down 21.29 points, 0.2%, at 8,717.97. The FTSE 250 ended down 90.94 points, 0.4%, at 20,708.72, and the AIM All-Share closed down 0.70 points, 0.1%, at 736.04. The Cboe UK ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then immediately hatched a plan to replace it with a late-stage candidate for metabolic dysfunction-associated steatohepatitis ...